



Kilitch Drugs (India) Ltd.

19th May, 2025

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Outcome of the Board Meeting

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that Board of Directors of the Company, at its meeting held today i.e. 19th May, 2025 have considered and approved the following;

1. Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2025. The copy of Audited Financial Results (Standalone and Consolidated) as adopted and approved by the Board of Directors and Auditor's report thereon are attached herewith for your ready reference.
2. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified (i.e., unqualified) opinion on the Financial Statements (Standalone and Consolidated) for the year ended on 31st March, 2025.

The Board Meeting commenced at 16:30 hrs and concluded at 21:05 hrs

Request you to kindly take note of the same and acknowledge the receipt.

Thanking You,

Yours faithfully,

For Kilitch Drugs (India) Limited

Bhavin Mehta
Wholetime Director
DIN: 00147895



Independent Auditor's Report on Audit of Quarterly and Annual Standalone Financial Results of Kilitch Drugs (India) Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

Opinion

We have audited the accompanying Statement of Standalone Audited Financial Results for the quarter/ year ended March 31, 2025 (refer 'Other Matter' section below) of **Kilitch Drugs (India) Limited** ("the Company") ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:



- i. is presented in accordance with requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other
- iii. accounting principles generally accepted in India, of the net profit, other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, (as amended) ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Standalone Financial Results

The statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the accounting standards specified under section 133 of the Act, read with the relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making



judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statements, Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statements as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for purpose of expressing an opinion on the effectiveness of the Company's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Board of Directors.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence



obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

1. The Standalone financials result of the Company of the quarter and year ended March 31, 2024 were audited by the predecessor auditor, M/s. Suaryaprakash Maurya & Co. who have expressed an unmodified opinion on the financial results.
2. The statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a **limited review by us**, as required under the Listing Regulations.

Our opinion is not modified in respect of this matter.

As per our report of even date

For C. Sharat & Associates

Chartered Accountants

Reg No : 128593W



Chintan Sharatchandra Shah

Partner

M. No - 127551

UDIN : 25127551BMMIJC7295

Place : Mumbai

Date : 19-05-2025



KILITCH DRUGS (INDIA) LIMITED
STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31ST MARCH, 2025

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718


(Rs. In Lakhs except Earnings per Share data)

		Three Months Ended			Year Ended	
		31/03/2025	31/12/2024	31/03/2024	31/03/2025	31/03/2024
		Audited	Unaudited	Audited	Audited	Audited
1	Income					
	Net Sales/ Income from operations	5,630.41	4,651.32	3,913.55	18,158.73	13,159.90
	Other Income	232.47	237.00	89.63	1,371.53	618.85
	Total Income	5,862.88	4,888.32	4,003.18	19,530.26	13,778.75
2	Expenses					
	Cost of Materials Consumed	2,712.76	2,449.58	2,240.73	9,319.06	6,633.24
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(145.03)	22.48	(33.81)	(116.99)	(11.61)
	Employee Benefit Expenses	258.29	273.02	190.81	1,003.07	791.35
	Finance Cost	72.10	49.42	44.49	212.55	190.81
	Depreciation and Amortisation Expenses	51.06	47.49	41.03	173.72	124.42
	Export Product Registration/Commission	643.35	416.19	561.81	1,994.23	1,392.62
	Other Expenses	770.47	678.23	432.35	2,875.63	2,322.61
	Total Expenses	4,363.00	3,936.41	3,477.41	15,461.27	11,443.44
3	Profit / (Loss) before Exceptional items (1-2)	1,499.88	951.91	525.77	4,068.99	2,335.31
4	Exceptional Items	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	1,499.88	951.91	525.77	4,068.99	2,335.31
6	Less: Tax Expenses:-					
	Current Tax	355.86	286.55	131.50	985.00	636.50
	Deferred Tax	6.61	(22.94)	30.08	(31.70)	(58.57)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	1,137.41	688.30	364.19	3,115.69	1,757.38
8	Other Comprehensive Income (after tax)	(93.40)	(123.10)	103.47	(113.68)	556.13
9	Total Comprehensive Income (after taxes) (7+8)	1,044.01	565.20	467.66	3,002.01	2,313.51
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,608.23	1,608.23	1,608.23	1,608.23	1,608.23
11	Other Equity	-	-	-	23,686.14	20,684.13
12	Earning per share (not annualised)					
	(a) Basic	7.07	4.28	2.26	19.37	11.03
	(b) Diluted	7.07	4.28	2.26	19.37	11.03

Notes:

- The above Audited Standalone Financial Results of the Company for the quarter / year ended 31st March, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 19th May, 2025.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the quarter ended 31st March, 2025 and 31st March, 2024 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2025 and 31st March, 2024 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.

Place : Mumbai
Dated: 19th May, 2025



For and on behalf of the Board of Directors

Bhavin Mehta
Wholtime Director
DIN:- 00147895



KILITCH DRUGS (INDIA) LIMITED
AUDITED STANDALONE BALANCE SHEET AS AT 31ST MARCH 2025
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	As on 31st March, 2025	As at 31st March, 2024
	Audited	Audited
ASSETS		
Non-current assets		
- Property, Plant and Equipment	1,915.75	1,525.79
- Capital work-in-progress	4,729.45	596.50
- Other Intangible Assets	35.14	44.42
Financial assets		
- Investments	7,185.10	7,127.27
- Loans/Advances	5,423.15	5,046.95
- Other Financial Assets	1.81	1.25
Deferred tax assets (Net)	287.64	255.95
(A)	19,578.03	14,598.13
Current Assets		
- Inventories	1,530.96	398.80
Financial assets		
- Investments	4,951.77	4,942.84
- Trade Receivables	8,339.83	6,180.46
- Cash & Cash Equivalents	740.85	1,794.88
- Other Bank Balances	4.73	68.08
- Other Financial Assets	3.20	3.37
Other Current Assets	666.42	760.50
(B)	16,237.76	14,148.93
TOTAL ASSETS (A + B)	35,815.79	28,747.06
EQUITY AND LIABILITIES		
Equity		
- Equity Share Capital	1,608.23	1,608.23
- Other Equity	23,686.14	20,684.13
(A)	25,294.37	22,292.36
Liabilities		
Non-Current liabilities		
Financial Liabilities		
- Borrowings	2,777.04	-
Provisions	24.53	17.24
(B)	2,801.57	17.24
Current liabilities		
Financial Liabilities		
- Borrowings	2,132.43	3,131.71
- Trade Payables		
Micro and Small Enterprises	-	-
Others	4,742.22	2,616.12
- Other Financial Liabilities	7.03	7.80
Provisions	143.79	130.70
Current Tax Liabilities [Net]	668.55	530.51
Other Current Liabilities	25.84	20.62
(C)	7,719.85	6,437.46
TOTAL EQUITY AND LIABILITIES (A+B+C)	35,815.79	28,747.06

For and on behalf of the Board of Directors

Chintan Shah



Bhavin Mehta

Bhavin Mehta
Wholetime Director
DIN:- 00147895



Place : Mumbai
Dated: 19th May, 2025

KILITCH DRUGS (INDIA) LIMITED
AUDITED STANDALONE CASH FLOW STATEMENT FOR YEAR ENDED 31ST MARCH, 2025
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	Year Ended 31st March, 2025		Year Ended 31st March, 2024	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		4,068.99		2,335.32
<i>Adjustments for:</i>				
Depreciation and amortization	173.72		124.42	
Interest income	(358.74)		(211.75)	
Dividend income	(0.55)		(1.20)	
(Profit)/Loss on sale of Investments	(652.17)		(138.85)	
Provision for Gratuity & Leave Encashment	0.44		0.50	
Interest Expenses	212.55		190.81	
Provision for Expected Credit Loss	115.96		238.06	
(Profit) / Loss from Investment in Partnership Firm	0.04		0.20	
Net unrealised exchange (gain) / loss	(59.99)	(568.75)	(15.85)	186.34
Operating profit / (loss) before working capital changes		3,500.24		2,521.66
<i>Changes in working capital:</i>				
<i>Operating Assets:</i>				
Inventories	(1,132.16)		(194.34)	
Trade receivables	(2,215.35)		(1,092.45)	
Other current assets	94.07		(517.34)	
Deposits & advances	(29.51)		(9.45)	
Other financial assets	0.17		(1.21)	
<i>Operating Liabilities:</i>				
Trade payables	2,126.09		(267.52)	
Other current liabilities	4.45		11.76	
Provisions	22.22	(1,130.01)	(5.73)	(2,076.28)
Gross cash flow from / (used in) operating activities		2,370.23		445.39
Direct Taxes (Paid) /refunded		(846.95)		(703.55)
Net cash flow from / (used in) operating activities (A)		1,523.28		(258.16)
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchases of Property, Plant & Equipment and CWIP	(4,687.34)		(652.04)	
Loans/Advances to related Parties	(346.69)		(220.36)	
Proceeds/(Purchases) (Net) of Current Investments	527.33		(139.45)	
Proceeds/(Purchases) (Net) of Non-Current Investments	(57.87)		(17.71)	
Movement in other Bank balances	62.79		(54.14)	
Interest received	358.74		211.75	
Dividend received	0.55		1.20	
		(4,142.49)		(870.75)
		(4,142.49)		(870.75)
Net cash flow from / (used in) investing activities (B)		(4,142.49)		(870.75)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Equity Share Capital issued - incl. Premium	-		385.75	
(Net of conversion of Appl. Money on warrants received)				
Proceeds from Borrowings (Net of Repayments)	1,777.74		945.28	
Interest paid	(212.55)		(190.81)	
Net cash flow from / (used in) financing activities (C)		1,565.19		1,140.22
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(1,054.03)		11.31
Cash and cash equivalents at the beginning		1,794.88		1,783.58
Cash and cash equivalents at the end		740.85		1,794.88
Cash and cash equivalents at the end *				
* Comprises:				
(a) Cash on hand		3.58		1.11
(b) Balances with banks				
(i) In current accounts		733.45		1,789.93
(ii) In earmarked accounts		3.82		3.84
		740.85		1,794.88

Place: Mumbai
Dated: 19th May, 2025



For and on behalf of the Board of Directors

Bhavin Mehta

Bhavin Mehta
Wholetime Director
DIN:- 00147895



Independent Auditor's Report on Audit of Quarterly and Annual Consolidated Financial Results of Kilitch Drugs (India) Limited ("the Parent") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited,

Opinion

We have audited the accompanying Statement of "Audited Consolidated Financial Results for the Quarter/Year ended March 31, 2025" (refer paragraph 3 of 'Other Matters' section below) of **Kilitch Drugs (India) Limited** ('the Parent') which includes its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive income/loss of its associates for the quarter and year ended March 31, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements/financial results/financial information of the subsidiaries, the statement:



i. includes the results of entities as given below:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
 2. Kilitch Estro Biotech PLC – Foreign Subsidiary
- ii. is presented in accordance with requirements of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit, other comprehensive Income and other financial information of the Group for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (as amended) (the "Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group, its associates in accordance with the "Code of Ethics" issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Consolidated Financial Results

This Statement is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Statement has been compiled from the related audited consolidated interim financial information for the quarter and year ended 31 March, 2025. This responsibility includes the preparation and presentation of the Statement that give a true and fair view of the consolidated net profit and consolidated other comprehensive loss and other financial information of the Group including its associates in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group and of its associates are responsible for assessing the ability of the Group and of its associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates is also responsible for overseeing the financial reporting process to the Group and of its associates.

Auditor's Responsibility for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Board of Directors.
- Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and of its associates to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statements, including the disclosures, and whether the statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated 29th March, 2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the financial information/financial results of the entities within the Group and its associates, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.



We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated 29th March, 2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable

Other Matters


1. The Consolidated financials result of the Company of the quarter and year ended March 31, 2024 were audited by the predecessor auditor, M/s. Suaryaprakash Maurya & Co. who have expressed an unmodified opinion on the financial results.
2. The accompanying Statement includes the audited financial results/statements and other financial information, in respect of:

One subsidiary, whose financial results/statements reflect total assets of Rs. 1,857.10 lakhs as at March 31, 2025, total revenues of Rs. Nil and Rs Nil, total Net Profit/(Loss) after tax of Rs. (22.45) lakhs and Rs. (88.19) lakhs, total comprehensive loss of Rs. (22.45) lakhs and Rs. (88.19) lakhs, for the quarter and the year ended on that date respectively, and net cash outflows of Rs. 0.01 lakhs for the year ended March 31, 2025 as considered in the Statement which have been audited by their respective independent auditors.

The independent auditor's report on the financial statements of the entity have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of such auditor and the procedures performed by us as stated in paragraph above.

3. The accompanying Statement includes unaudited financial results /statements and other unaudited financial information in respect of:

One foreign subsidiary, whose financial results/statements reflect total assets of Rs. 5,341.53 lakhs as at March 31, 2025, total revenues of Rs. 788.51 and Rs. 1,971.83 lakhs, total Net Profit/(Loss) after tax of Rs. (54.78) lakhs and Rs (533.48) lakhs, total comprehensive loss of Rs. (54.78) lakhs and Rs. (533.48) lakhs, for the quarter and the year ended on that date respectively, and net cash inflows of Rs. 137.91 lakhs for the year ended March 31, 2025 as considered in the Statement which have been audited by their respective independent auditors.




These unaudited financial statements / financial results have been approved and furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on such unaudited financial statements/ financial results.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors in Para 2 and the unaudited Financial Results/ Financial Statements certified by the Management referred in Para 3 above.

4. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the Statement is not modified in respect of this matter.

As per our report of even date
For C. Sharat & Associates
Chartered Accountants
Reg No : 128593W



Chintan Sharatchandra Shah
Partner
M. No - 127551
UDIN : 25127551BMIIJD5977
Place : Mumbai
Date : 19-05-2025

KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31ST MARCH, 2025

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED				
		Three Months Ended			Year Ended	
		31/03/2025	31/12/2024	31/03/2024	31/03/2025	31/03/2024
	Audited	Unaudited	Audited	Audited	Audited	
1	Income					
	Net Sales/Income from Operations	6,122.58	5,616.61	4,481.88	19,831.85	15,437.25
	Other Income	169.75	172.52	47.12	1,116.06	447.89
	Total Income	6,292.33	5,789.13	4,529.00	20,947.91	15,885.14
2	Expenses					
	Cost of Materials Consumed	3,014.73	3,253.57	2,509.45	10,574.97	7,907.82
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(145.02)	22.48	(33.81)	(116.99)	(11.61)
	Employee Benefit Expenses	288.06	314.19	237.14	1,132.38	1,001.31
	Finance Cost	160.13	140.30	132.23	504.13	592.94
	Depreciation and Amortisation Expenses	84.67	80.74	92.91	311.02	334.96
	Export Product Registration/Commission	643.47	416.28	561.79	1,995.02	1,395.25
	Other expenses	861.91	736.49	499.60	3,099.96	2,729.02
	Total Expenses	4,907.95	4,964.05	3,999.31	17,500.49	13,949.69
3	Profit before Exceptional items (1-2)	1,384.38	825.08	529.69	3,447.42	1,935.45
4	Exceptional Items	-	-	-	-	-
5	Profit from ordinary activities before tax (3+4)	1,384.38	825.08	529.69	3,447.42	1,935.45
6	Less : Tax Expenses					
	Current Income Tax	355.86	286.55	131.50	985.00	636.50
	Deferred Tax	6.66	(22.94)	30.12	(31.59)	(58.57)
7	Profit after tax for the period from continuing operations (5-6)	1,021.86	561.47	368.07	2,494.01	1,357.52
	Add/(Less): Share in Profits /(Loss) of Associates	-	-	-	-	-
8	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of Associates	1,021.86	561.47	368.07	2,494.01	1,357.52
9	Other Comprehensive Income (after Tax)	(93.40)	(123.10)	103.48	(113.68)	556.13
10	Total Comprehensive Income (after taxes) (8+9)	928.46	438.37	471.55	2,380.33	1,913.65
11	Net Profit / (Loss) attributable to					
	a) Owner of the Company	1,039.94	596.09	359.42	2,670.06	1,460.14
	b) Non Controlling interest	(18.08)	(34.62)	8.65	(176.05)	(102.62)
12	Other Comprehensive Income attributable to					
	a) Owner of the Company	(93.40)	(123.10)	103.48	(113.68)	556.13
	b) Non Controlling interest	-	-	-	-	-
13	Total Income attributable to					
	a) Owner of the Company	946.54	472.99	462.90	2,556.38	2,016.27
	b) Non Controlling interest	(18.08)	(34.62)	8.65	(176.05)	(102.62)
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,608.23	1,608.23	1,608.23	1,608.23	1,608.23
15	Other Equity				18,624.68	16,020.89
16	Earning per share (not annualised)					
	(a) Basic	6.47	3.71	2.24	16.60	9.17
	(b) Diluted	6.47	3.71	2.24	16.60	9.17

Notes:

- The above audited Consolidated Financial Results of the Company for the quarter/year ended 31st March, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 19th May, 2025.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
The figures for the quarter ended 31st March, 2025 and 31st March, 2024 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2025 and 31st March, 2024 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.

Place: Mumbai
 Date: 19th May, 2025



For and on behalf of the Board of Directors

Bhavin Mehta
 Bhavin Mehta
 Wholetime Director
 DIN:- 00147895



KILITCH DRUGS (INDIA) LIMITED		
AUDITED CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2025		
CIN:L24239MH1992PLC066718		
(Rs. In Lakhs)		
Particulars	As at 31st March, 2025	As at 31st March, 2024
	Audited	Audited
ASSETS		
Non-current assets		
Property, plant and Equipment	4,552.43	4,215.52
Capital work-in-progress	4,729.45	596.50
Other Intangible assets	1,888.74	1,982.28
Financial assets		
- Investments	2,284.19	2,283.48
- Loans/Advances	142.19	71.51
- Other Financials Assets	1.81	1.25
Deferred tax assets (Net)	287.92	256.34
(A)	13,886.73	9,406.88
Current assets		
Inventories	1,530.96	398.80
Financial assets		
- Investments	4,951.77	4,942.84
- Trade and other receivables	8,473.88	6,322.38
- Cash and cash equivalents	980.05	1,896.18
- Other Bank Balances	4.73	68.08
- Other Financials Assets	3.20	3.37
Other current assets	1,447.06	967.63
(B)	17,391.65	14,599.28
TOTAL ASSETS (A + B)	31,278.38	24,006.16
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	1,608.23	1,608.23
Other Equity	18,624.68	16,020.89
Equity attributable to the owners		
Non-controlling interest	(187.11)	(61.79)
(A)	20,232.91	17,629.12
Liabilities		
Non-current liabilities		
Financial liabilities		
- Borrowings	2,777.04	-
Provisions	24.53	17.24
(B)	2,801.57	17.24
Current liabilities		
Financial liabilities		
- Borrowings	2,165.36	3,164.65
- Trade Payables	-	-
Micro and Small Enterprises	-	-
Others	5,415.74	2,558.89
- Other financial liabilities	7.03	7.80
Provisions	148.48	139.12
Current tax Liabilities (Net)	668.55	530.51
Other current liabilities	25.85	20.62
(C)	8,431.01	6,421.59
TOTAL EQUITY AND LIABILITIES (A + B + C)	31,278.38	24,006.16

For and on behalf of the Board of Directors

Muram

Bhavin Mehta

Place : Mumbai
Date : 19th May, 2025

Bhavin Mehta
Wholetime Director
DIN:- 00147895



KILITCH DRUGS (INDIA) LIMITED
AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2025
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs)

Particulars	For the Year ended 31st March 2025		For the Year ended 31st March 2024	
	Audited		Audited	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		3,447.43		1,935.45
Adjustments for:				
Depreciation and amortisation	311.02		334.96	
Interest income	(102.56)		(40.74)	
Dividend income	(0.55)		(1.20)	
(Profit)/Loss on sale of Investments	(652.17)		(138.05)	
Share of (Profit)/ Loss from Partnership Firm	0.04		0.20	
Provision for Gratuity & Leave Encashment	0.44		0.50	
Interest Expenses	504.13		592.94	
Bad Debts / Provision for Doubtful Debts	115.96		313.88	
Net unrealised exchange (gain) / loss	(59.99)	116.32	(15.85)	1,045.83
Operating profit / (loss) before working capital changes		3,563.76		2,981.28
Changes in working capital:				
Operating Assets:				
Inventories	(1,132.16)		(194.34)	
Trade receivables	(2,207.48)		(1,191.71)	
Other current assets	(432.07)		187.07	
Deposit & Advances	(70.67)		(9.45)	
Operating Liabilities:				
Trade payables	2,856.85		(1,228.55)	
Other financial liabilities	(0.77)		3.93	
Other current liabilities	5.23		(0.50)	
Short-term provisions	18.49	(962.58)	2.33	(2,431.22)
Gross cash flow from / (used in) operating activities		2,601.18		550.05
Direct Taxes (Paid) / refunded		(846.95)		(703.55)
Net cash flow from / (used in) operating activities		1,754.23		(153.50)
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on PPE,CWIP including capital advances	(4,687.34)		(645.04)	
Proceeds (Net) from the sale of Current investments	527.33		(139.45)	
(Purchase)/Sale (Net) of long-term investments:	(0.75)		(17.71)	
Movement in other Bank balance	62.79		(54.14)	
Interest received	102.73		39.52	
Dividend received	0.55		1.20	
		(3,994.69)		(815.62)
Net cash flow from / (used in) investing activities (B)		(3,994.69)		(815.62)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Equity Share Capital issued - incl. Premium (Net of conversion of Appl. Money on warrants received)Proceeds from Shares issued (incl. ESOPs)	-		385.75	
Proceeds from Borrowings (Net of Repayments)	1,777.75		945.29	
Proceeds from Minorities	50.71		142.57	
Interest paid	(504.13)		(592.94)	
		1,324.33		880.67
Net cash flow from / (used in) financing activities (C)		1,324.33		880.67
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(916.13)		(88.43)
Cash and cash equivalents at the beginning of the year		1,896.18		1,984.60
Cash and cash equivalents at the end of the year		980.05		1,896.18
Cash and cash equivalents at the end of the year *				
* Comprises:				
(a) Cash on hand		3.58		1.24
(b) Balances with banks				
(i) In current accounts		972.65		1,891.10
(ii) In earmarked accounts		3.82		3.84
		980.05		1,896.18

Chintan Shah



Place : Mumbai
Date : 19th May, 2025

For and on behalf of the Board of Directors

Bhavin Mehta

Bhavin Mehta
Wholetime Director
DIN:- 00147895

